Adaptive Biotechnologies Corp(ADPT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.41 | Insider Own | 2.96% | Shs Outstand | 159.1M | Perf Week | 13.27% |
| Market Cap | 4.41B | Forward P/E | - | EPS next Y | 67.99% | Insider Trans | -35.72% | Shs Float | 154.9M | Perf Month | -2.98% |
| Enterprise Value | 4.49B | PEG | - | EPS next Q | -0.09 | Inst Own | 97.52% | Short Float | 7.74% | Perf Quarter | 22.61% |
| Income | -0.06B | P/S | 14.33 | EPS this Y | -38.37% | Inst Trans | 2.31% | Short Ratio | 5.42 | Perf Half Y | 97.01% |
| Sales | 0.31B | P/B | 30.78 | EPS next 5Y | - | ROA | -11.23% | Short Interest | 11.99M | Perf YTD | 70.32% |
| Book/sh | 0.9 | P/C | 12.82 | EPS past 3/5Y | 34.64% 18.85% | ROE | -39.58% | 52W High | -10.02% ($30.74) | Perf Year | 61.57% |
| Cash/sh | 2.16 | P/FCF | - | Sales past 3/5Y | 14.34% 23% | ROIC | -11.73% | 52W Low | 130.5% ($12.00) | Perf 3Y | 550.82% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 50.4% | Gross Margin | 72.71% | Volatility(W/M) | 6.68% 5.86% | Perf 5Y | -14.52% |
| Dividend TTM | - | EV/Sales | 14.57 | Sales Y/Y TTM | 50.13% | Oper. Margin | -11.81% | ATR (14) | 1.46 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.68 | EPS Q/Q | -47.8% | Profit Margin | -20.73% | RSI (14) | 57.94 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.79 | Sales Q/Q | 21.53% | SMA20 | 5.6% ($26.19) | Beta | 2.18 | Target Price | $30.21 |
| Payout | - | Debt/Eq | 2.87 | Earnings | 2026/11/4 | SMA50 | 5.47% ($26.23) | Rel Volume | 0.69 | Prev Close | $26.27 |
| Employees | 624 | LT Debt/Eq | 2.81 | EPS/Sales Surpr. | -87.13% 9.35% | SMA200 | 42.14% ($19.46) | Avg Volume(3M) | 2.21M | Price | $27.66 |
| IPO | 2019/6/27 | Option/Short | Yes/Yes | Trades | 15085 | Volume | 1,535,163 | Change | 5.29% |
🧬 This is a US diagnostics company that develops immune-based diagnostics. It develops and provides minimal residual disease (MRD) diagnostics and immune medicine solutions using immune sequencing technology, giving it exposure to diagnostic test demand and commercialization. It is a company in the immune-based diagnostics space.
Over the past 1 year, on the higher side
10% below its 1-year high.
Traded less than usual. That is 69% of its average volume.
Next earnings report: November 4
7 days to go.
ADPT has a sound balance sheet but weak earning power
Of every $100 in sales, $11.81 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -38.4% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,433. Peers typically go for $451.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -14.5%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 97.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #22 of 44 in the industry
Based on market cap of $4B.
BLLN#20 Billiontoone Inc $5B PER 185.2 
SHC#21 Sotera Health Co $5B PER 32.5 ADPT#22 Adaptive Biotechnologies Corp $4B PER - 
VCYT#23 Veracyte Inc $4B PER 35.7 
CDNA#24 Caredx Inc $4B PER 34.0 
FAQ
What kind of company is ADPT?
ADPT belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of ADPT?
The market cap of ADPT is approximately $4.4B, ranking 1,449 within its sector.
What is the 52-week high and low for ADPT?
ADPT has recorded a 52-week high of $30.74 and a low of $12.00.
